Mark Warren, MD
Endocrinology, Diabetes & Metabolism · Greenville, NCNPI 1629073010
Payments from drug & device makers
Across 5,144 payments — averaging $979.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk AS$1.2M
- Medtronic$437K
- AbbVie$377K
- Senseonics, Incorporated$367K
- AstraZeneca$356K
- Eli Lilly$334K
- plus $2M from 54 others
Across 49 payments — averaging $467.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$15K
- Novo Nordisk AS$4K
- AbbVie$2K
- Regeneron$2K
What the payments were for
- Consulting fees$77,5168%
- Speaking & faculty fees$717,28878%
- Travel & lodging$88,52210%
- Food & beverage$31,7753%
- Education$2690%
- Other$180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$125,148
- EVENITY$88,331
- Yorvipath$85,669
- RYBELSUS$72,768
- Repatha$63,533
- Prolia$61,339
- LYUMJEV$31,615
- FREESTYLE LIBRE 3$28,139
- FARXIGA$27,369
- SOLIQUA 100/33$26,661
- NATPARA (PARATHYROID HORMONE)$22,372
- STEGLATRO$20,994
- MOUNJARO$20,712
- NEXLIZET$12,552
- NEXLETOL$12,552
- FreeStyle Libre Pro$10,300
- TOUJEO$10,250
- AFREZZA$8,931
- FreeStyle Libre 2$7,261
- Tresiba$6,973
How this compares
$5,039,497 in reported general payments places this provider in the 95th percentile of 232 endocrinology, diabetes & metabolism providers in North Carolina.
See all endocrinology, diabetes & metabolism providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 821 | $1,044,661 |
| KorlymMifepristone | 17 | $547,901 |
| Tresiba Flextouch U-200Insulin Degludec | 261 | $336,723 |
| TrulicityDulaglutide | 235 | $289,146 |
| JardianceEmpagliflozin | 226 | $206,190 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 113 | $146,191 |
| FarxigaDapagliflozin Propanediol | 172 | $133,355 |
| Tresiba Flextouch U-100Insulin Degludec | 237 | $132,367 |
| MounjaroTirzepatide | 94 | $126,989 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 74 | $110,355 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 74 | $110,147 |
| Repatha SureclickEvolocumab | 146 | $109,768 |
| RybelsusSemaglutide | 84 | $101,827 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 50 | $99,955 |
| Bydureon BciseExenatide Microspheres | 72 | $75,701 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Xultophy 100-3.6, Fiasp, Novolog | $231,500 | $1,300,1851,125 claims |
| Corcept TherapeuticsKorlym | $383 | $547,90117 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Lyumjev, Humalog | $92,074 | $506,126495 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $255,298 | $274,700299 claims |
| AstraZenecaFarxiga | $355,962 | $133,355172 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $37,723 | $110,14774 claims |
| MerckJanuvia, Janumet Xr | $21,566 | $93,47888 claims |
| Johnson & JohnsonInvokana | $39 | $57,97754 claims |
| Mannkind CorporationAfrezza | $9,592 | $28,95223 claims |
| PfizerEliquis | $13,037 | $28,68324 claims |
| AbbVieSynthroid | $376,732 | $22,735260 claims |
| BayerKerendia | $41,964 | $18,81614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 232 endocrinology, diabetes & metabolism providers in North Carolina.
Other endocrinology, diabetes & metabolism in Greenville
- Kathryn LucasMorehead City$37.9M
- Mary LawrenceMorehead City$4.9M
- John ParkerWilmington$4.1M
- John BuseChapel Hill$3.8M
- Wendy LaneAsheville$1.9M
- Anthony BarberHickory$1.4M
- Klara KleinChapel Hill$1.3M
- Thomas OconnellBurlington$805K
- Corey BerlinRaleigh$742K
- Michael FavoritoWilmington$723K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.